ORAL CONTRACEPTIVES, HORMONAL RISK FACTORS AND BRCA1

口服避孕药、激素风险因素和 BRCA1

基本信息

  • 批准号:
    6563754
  • 负责人:
  • 金额:
    $ 15.75万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2002
  • 资助国家:
    美国
  • 起止时间:
    2002-02-01 至 2003-01-31
  • 项目状态:
    已结题

项目摘要

Description: (Applicant's Description) Project C: Oral Contraceptives, Hormonal Risk Factors, and BRCA1. Mutations in the breast cancer susceptibility gene BRCA1 may be involved in a substantial number of breast cancers diagnosed at an early age. However, the age at which breast cancer occurs appears to vary substantially, even in women from the same family with the same mutation. This suggests that other, genetic or non-genetic, factors play a role in whether or when breast cancer occurs in women with a BRCA1 mutation. Epidemiological evidence suggests that oral contraceptive (OC) use at an early age may increase risk of breast cancer. Further, OC use may be particularly detrimental in women with a family history. A number of environmental risk factors other than exogenous hormone use probably also work through a hormonal mechanism; these include age at first birth, parity, possibly abortion, and physical exercise. All these factors can be manipulated, and therefore have implications for prevention. These "hormonal" risk factors appear to have different, if not opposite, effects in women with a family history than in women with no such history. The reason for this is unknown. However, BRCA1 expression appears to be regulated by hormones in experimental studies. Further, women with a family history are more likely to have a BRCA1 mutation. It is therefore possible that the apparent effect modification by family history is caused by BRCA1 status. We propose to conduct a population-based study that investigates whether the presence of specific BRCA1 mutations modify 1) the effects of oral contraceptive use, 2) the effects of "hormonal" risk factors such as age at first birth, number of pregnancies, and number of abortions, and 3) the protective effect of physical exercise, on breast cancer risk. In addition, this study will provide information as to the frequency of these mutations in younger breast cancer patients, and we will explore the associations between BRCA1 status and other breast cancer risk factors such as mammographic densities. This study will provide valuable epidemiologic information regarding the role of BRCA1 in breast cancer etiology, and could yield important results in developing intervention regimens and appropriate counseling for women with a BRCA1 mutation.
项目说明:(申请人说明)项目C:口服避孕药;

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

GISKE URSIN其他文献

GISKE URSIN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('GISKE URSIN', 18)}}的其他基金

Mammographic density, genes and estradiol/norethisterone based EPT regimens
乳房 X 光密度、基因和基于雌二醇/炔诺酮的 EPT 方案
  • 批准号:
    7263829
  • 财政年份:
    2007
  • 资助金额:
    $ 15.75万
  • 项目类别:
Mammographic density, genes and estradiol/norethisterone based EPT regimens
乳房 X 光密度、基因和基于雌二醇/炔诺酮的 EPT 方案
  • 批准号:
    7382492
  • 财政年份:
    2007
  • 资助金额:
    $ 15.75万
  • 项目类别:
HT, Mammographic Densites and Breast Cancer
HT、乳腺 X 光检查密度和乳腺癌
  • 批准号:
    6999266
  • 财政年份:
    2005
  • 资助金额:
    $ 15.75万
  • 项目类别:
GENES AND THE ESTROGEN EFFECT ON ENDOMETRIAL CANCER
基因和雌激素对子宫内膜癌的影响
  • 批准号:
    7006977
  • 财政年份:
    2002
  • 资助金额:
    $ 15.75万
  • 项目类别:
ORAL CONTRACEPTIVES, HORMONAL RISK FACTORS AND BRCA1
口服避孕药、激素风险因素和 BRCA1
  • 批准号:
    6152462
  • 财政年份:
    1999
  • 资助金额:
    $ 15.75万
  • 项目类别:
BRCA1, ORAL CONTRACEPTIVES, AND HORMONAL RISK FACTORS
BRCA1、口服避孕药和激素风险因素
  • 批准号:
    6164241
  • 财政年份:
    1999
  • 资助金额:
    $ 15.75万
  • 项目类别:
BRCA1, ORAL CONTRACEPTIVES, AND HORMONAL RISK FACTORS
BRCA1、口服避孕药和激素风险因素
  • 批准号:
    2741610
  • 财政年份:
    1999
  • 资助金额:
    $ 15.75万
  • 项目类别:
BRCA1, ORAL CONTRACEPTIVES, AND HORMONAL RISK FACTORS
BRCA1、口服避孕药和激素风险因素
  • 批准号:
    6362627
  • 财政年份:
    1999
  • 资助金额:
    $ 15.75万
  • 项目类别:
ESTROGEN METABOLISM IN A MULTIETHNIC POPULATION
多民族人群中的雌激素代谢
  • 批准号:
    2114511
  • 财政年份:
    1995
  • 资助金额:
    $ 15.75万
  • 项目类别:
HT, Mammographic Densites and Breast Cancer
HT、乳腺 X 光检查密度和乳腺癌
  • 批准号:
    7907848
  • 财政年份:
  • 资助金额:
    $ 15.75万
  • 项目类别:

相似海外基金

Pathology of Breast Neoplasms determined by MRS
MRS 测定乳腺肿瘤的病理学
  • 批准号:
    nhmrc : 950215
  • 财政年份:
    1995
  • 资助金额:
    $ 15.75万
  • 项目类别:
    NHMRC Project Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了